DexCom, Inc. $DXCM Shares Sold by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 12.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 272,836 shares of the medical device company’s stock after selling 37,468 shares during the period. Beacon Investment Advisory Services Inc. owned 0.07% of DexCom worth $18,108,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Twin Peaks Wealth Advisors LLC acquired a new position in shares of DexCom in the 2nd quarter valued at $26,000. SJS Investment Consulting Inc. lifted its position in DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 384 shares during the last quarter. Financial Consulate Inc. acquired a new position in DexCom in the third quarter valued at $29,000. CVA Family Office LLC boosted its stake in DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares in the last quarter. Finally, Spire Wealth Management grew its holdings in shares of DexCom by 113.8% during the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after purchasing an additional 305 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Canaccord Genuity Group set a $95.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, February 13th. Weiss Ratings upgraded DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $86.00 price objective (up from $84.00) on shares of DexCom in a research note on Friday, January 9th. Finally, Barclays reissued an “underweight” rating and issued a $72.00 price objective (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $86.50.

DexCom Stock Performance

NASDAQ DXCM opened at $62.25 on Monday. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The business’s 50-day moving average price is $70.06 and its 200 day moving average price is $67.57. The firm has a market cap of $23.96 billion, a P/E ratio of 29.64, a P/E/G ratio of 1.21 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the prior year, the business earned $0.45 EPS. The firm’s revenue was up 13.1% compared to the same quarter last year. On average, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $64.85, for a total transaction of $110,245.00. Following the completion of the sale, the executive vice president directly owned 112,904 shares of the company’s stock, valued at $7,321,824.40. This trade represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.32% of the stock is owned by company insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.